Loading...
Please wait, while we are loading the content...
Similar Documents
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
| Content Provider | Scilit |
|---|---|
| Author | Hochhaus, Andreas Ernst, Thomas |
| Copyright Year | 2021 |
| Description | Treatment-free remission (TFR) is a new and significant goal of chronic myeloid leukemia management. TFR should be considered for patients in stable deep molecular response (DMR) after careful discussion in the shared decision-making process. Second-generation tyrosine kinase inhibitors (TKIs) improve the speed of response and the incidence of DMR. Treatment may be changed to a more active TKI to improve the depth of response in selected patients who have not reached DMR. Stem cell persistence is associated with active immune surveillance and activation of BCR-ABL1-independent pathways, eg, STAT3, JAK1/2, and BCL2. Ongoing studies aim to prove the efficacy of maintenance therapies targeting these pathways after TKI discontinuation. |
| Related Links | https://ashpublications.org/hematology/article-pdf/2021/1/106/1851817/106hochhaus.pdf |
| Ending Page | 112 |
| Page Count | 7 |
| Starting Page | 106 |
| DOI | 10.1182/hematology.2021000238 |
| Journal | Hematology |
| Issue Number | 1 |
| Volume Number | 2021 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2021-12-10 |
| Access Restriction | Open |
| Subject Keyword | Anesthesiology Treatment Decision Making Tki Tfr Efficacy Dmr Discontinuation Free Remission Journal: Hematology (Vol- 41, Issue- 1) |
| Content Type | Text |
| Resource Type | Article |
